GHRP-2 vs Kisspeptin-10

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

GHRP-2Kisspeptin-10
CategoryPeptidesPeptides
Standard DoseResearch indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.
TimingOn empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.
Cycle Duration8-16 week cycles.Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.
Evidence Levelmoderate_humanmoderate_human
A

GHRP-2

Peptides

Mechanism

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide GHS-R1a agonist that is the most potent of the GHRP family for GH release. It stimulates pituitary GH secretion through the ghrelin receptor while also modulating hypothalamic GHRH and somatostatin pathways. GHRP-2 increases GH, cortisol, prolactin, and ACTH release, but with less appetite stimulation than GHRP-6. It also has demonstrated anxiolytic properties and sleep-promoting effects.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.

Cycle Duration

8-16 week cycles.

Side Effects

  • Water retention
  • Moderate hunger increase (less than GHRP-6)
  • Cortisol elevation
  • Prolactin elevation
  • Tingling
  • Vivid dreams

Contraindications

  • Active cancer
  • Cushing's syndrome
  • Hyperprolactinemia
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)SermorelinBPC-157
B

Kisspeptin-10

Peptides

Mechanism

Kisspeptin-10 is the 10-amino acid C-terminal fragment of the kisspeptin family that signals directly to GnRH neurons through the kisspeptin receptor (KISS1R/GPR54), triggering GnRH release into the portal circulation. This stimulates LH and FSH secretion from anterior pituitary gonadotrophs. In men, intravenous kisspeptin-10 produces rapid dose-dependent LH rises (4.1 to 12.4 IU/L at 1 mcg/kg within 30 minutes), increases LH pulse frequency and amplitude, and subsequently elevates testosterone through the HPG axis.

Standard Dosing

Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.

Timing

Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.

Cycle Duration

Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.

Side Effects

  • Facial flushing
  • Mild nausea
  • Elevated LH/testosterone (desired effect)
  • Potential for HPG axis desensitization with prolonged use

Contraindications

  • Hormone-sensitive cancers (prostate, breast)
  • Pregnancy and breastfeeding
  • Children/adolescents (premature puberty risk)

Best Stacking Partners

PT-141HCG

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →